Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
Jingquan JiaLauren HowardYingmiao LiuMark D StarrJohn C BradyDonna NiedzwieckiJohn H StricklerAndrew B NixonPublished in: Cancer chemotherapy and pharmacology (2022)
ClinicalTrials.gov identifier: NCT02008383.